Ahead of merg­er with Pfiz­er's gener­ic unit, My­lan makes $757M+ pur­chase for Eu­ro­pean throm­bo­sis port­fo­lio

My­lan is in­creas­ing its pres­ence in Eu­rope with a high-dol­lar ac­qui­si­tion of a blood clot port­fo­lio.

The gener­ic drug­mak­er is pay­ing more than three-quar­ters of a bil­lion dol­lars to gob­ble up As­pen Phar­ma­care’s throm­bo­sis busi­ness on the con­ti­nent. The ex­act sum of €641.9 mil­lion, or about $757 mil­lion, will be divvied up in­to an up­front pay­ment of about 41% of the to­tal, with the re­main­ing be­ing de­ferred to next June.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER